ReviewCancers2020
Adjuvant Chemotherapy for Stage II Colon Cancer.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.The New England journal of medicine · 2022Trial
- Proteomic Analysis of Paired FFPE Tissue and Extracellular Vesicles Reveals Proteins Associated with Recurrence in Stage II Colorectal Cancer.Journal of proteome research · 2026Article
- Adjuvant Tegafur-Uracil Improves Survival in Low-Risk, Mismatch Repair Proficient Stage IIA Colon Cancer: A Propensity Score-Matched Analysis.Life (Basel, Switzerland) · 2025Article
- Contemporary Use of ctDNA for the Colorectal Surgeon.Clinics in colon and rectal surgery · 2025Review
- HIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer.Nature communications · 2025Article
- Polo-Like Kinase 1 Expression in Colorectal Cancer: Association With RAS Mutations.Cancer science · 2025Article
- Regulation of Stemness by NR1D2 in Colorectal Cancer.Biomedicines · 2025Article
- Prognosis in stage II colon cancer: Expanding the horizons of risk factors.World journal of gastrointestinal oncology · 2025Article
- Diagnosis and Management of Colorectal Cancer in the Gulf Area: Current Practice and Future Suggestions from Expert Opinions.OncoTargets and therapy · 2025Review
- Molecular Biology of Cancer-Interplay of Malignant Cells with Emerging Therapies.International journal of molecular sciences · 2024Article
- The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer.International journal of molecular sciences · 2024Article
- Article
- Comment on Prognostic Relevance of Primary Tumor Sidedness in Early-Stage Colorectal Cancer: An Integrated Analysis of Four Randomized Controlled Trials (JCOG2003A).Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2024Article
- Acetone compression improves lymph node yield and metastasis detection in colorectal cancer.Clinical & experimental metastasis · 2024Article
- Principles of risk assessment in colon cancer: immunity is key.Oncoimmunology · 2024Review
- Delving into New Frontiers: assessing ChatGPT's proficiency in revealing uncharted dimensions of general surgery and pinpointing innovations for future advancements.Langenbeck's archives of surgery · 2023Article
- Prognostic Value of Serum Neutrophil to Lymphocyte Ratio and SUVmax in Stage I and II Colon Cancer.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse.Journal of translational medicine · 2023Article
- Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer.Cancer research communications · 2023Article
- Risk factors for postoperative recurrence in patients with stage II colorectal cancer.BMC cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In stage II colon cancer management, surgery alone has shown a high cure rate (about 80%), and the role of adjuvant chemotherapy is still a matter of debate. Patients with high-risk features (T4, insufficient nodal sampling, grading, etc.) have a poorer prognosis and, usually, adjuvant chemotherapy is recommended. The purpose of the present study is to highlight and discuss what is still unclear and not completely defined from the previous trials regarding risk stratification and therapeutic benefit of adjuvant chemotherapy. With all the limitations of generalizing, we make the effort of trying to quantify the relative contribution of each prognostic factor and the benefit of adjuvant chemotherapy for stage II colon cancer. Finally, we propose a decision algorithm with the aim of summarizing the current evidence and translating it to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.